Cold Plasma in Healthcare Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Wound Healing, Surgical Application and Other Medical Applications), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.59 Billion
CAGR (2026-2031)	12.78%
Fastest Growing Segment	Wound Healing
Largest Market	North America
Market Size (2031)	USD 5.33 Billion

Market Overview

The Global Cold Plasma in Healthcare Market is projected to grow from USD 2.59 Billion in 2025 to USD 5.33 Billion by 2031 at a 12.78% CAGR. Cold plasma in healthcare is defined as a non-thermal partially ionized gas generated at near-ambient temperatures, utilized for diverse medical applications including sterilization, chronic wound healing, and cancer therapy without causing thermal damage to viable tissues. The market is fundamentally supported by the escalating demand for non-invasive treatment modalities and the critical need for advanced infection control measures to combat antibiotic-resistant pathogens. According to the Association for Cleaning & Facility Solutions, in 2025, approximately one in ten patients globally contracted a healthcare-associated infection, a statistic that underscores the urgent industrial necessity for effective decontamination technologies like cold plasma.

Despite these strong growth propellants, the market faces a significant challenge regarding stringent regulatory frameworks governing medical device approvals. The complex and capital-intensive process of demonstrating clinical safety and efficacy to regulatory bodies creates substantial barriers to entry, potentially delaying the commercialization of innovative plasma systems and impeding broader market expansion.

Key Market Drivers

The rising prevalence of chronic wounds and diabetic ulcers is a primary catalyst for market expansion, necessitating advanced therapies beyond traditional wound care. Cold plasma devices are increasingly utilized to accelerate tissue regeneration and eliminate bacterial biofilms in non-healing lesions by generating reactive oxygen and nitrogen species. This demand is critically driven by the escalating global burden of metabolic diseases; according to the International Diabetes Federation, in 2025, approximately 589 million adults were living with diabetes worldwide, a condition directly correlated with high susceptibility to complex foot ulcers. The urgency for such alternative treatments is further amplified by the failing efficacy of standard antibiotics in wound management. According to the World Health Organization, in October 2025, antibiotic resistance had risen in over 40% of monitored pathogen-antibiotic combinations since 2018, a trend that underscores the industrial imperative for the non-pharmaceutical bactericidal mechanisms offered by cold plasma technology.

Simultaneously, the market is witnessing significant growth due to the emerging potential of cold plasma as a selective cancer treatment modality. Unlike conventional radiation or chemotherapy, cold atmospheric plasma can induce apoptosis in malignant cells through oxidative stress while leaving healthy tissue unharmed, presenting a revolutionary approach for solid tumor management. This clinical efficacy is beginning to yield tangible regulatory and trial successes. According to US Medical Innovations, in May 2024, phase I clinical trials for the FDA-cleared Canady Helios Cold Plasma System demonstrated a non-local recurrence rate of up to 80% in patients with advanced solid tumors. As research continues to validate these outcomes, the integration of plasma systems into oncological surgical protocols is expected to drive substantial investment into advanced electrosurgical generators and probes.

Download Free Sample Report

Key Market Challenges

The strict regulatory frameworks governing medical device approvals currently stand as a formidable impediment to the Global Cold Plasma in Healthcare Market. This challenge hampers market growth by creating high entry barriers that disproportionately affect the small and medium-sized enterprises often responsible for pioneering plasma technologies. The complex process of validating the safety of partially ionized gas applications necessitates capital-intensive clinical trials and lengthy review periods, which delays the commercial release of innovative therapies. As manufacturers navigate these arduous protocols, the return on investment becomes uncertain, causing potential investors to hesitate and slowing the overall pace of technological adoption.

The financial magnitude of this regulatory burden is substantial. According to MedTech Europe, in 2025, medical device manufacturers reported facing a 50% increase in the costs associated with regulatory maintenance and re-certification cycles due to evolving compliance standards. This sharp rise in operational expenditure forces companies to divert critical funds away from research and development to meet administrative requirements. Consequently, the market experiences constricted product pipelines and reduced expansion rates, as resources that could drive the next generation of cold plasma solutions are consumed by compliance obligations.

Key Market Trends

The Development of Portable and Handheld Plasma Devices is fundamentally altering the delivery of cold plasma therapies by shifting treatment from centralized hospital units to ambulatory and point-of-care settings. This trend is characterized by the miniaturization of high-voltage power supplies and gas reservoirs, allowing clinicians to administer plasma directly at a patient’s bedside or in remote locations. The industrial push towards mobility is evidenced by significant capital inflows aimed at scaling these compact technologies for global commercialization. According to Adtec Healthcare, July 2025, in the 'Adtec Healthcare Secures $12 Million Investment' announcement, the company secured $12 million in strategic funding to accelerate the development and US market entry of its next-generation handheld cold plasma devices. This targeted financial support highlights the industry's pivot towards flexible, user-centric systems that decouple advanced infection control from heavy capital equipment infrastructure.

Simultaneously, the Expansion into Aesthetic and Cosmetic Dermatology Applications is rapidly diversifying the market’s revenue streams beyond traditional therapeutic indications. Cold plasma is gaining traction as a non-invasive alternative for skin rejuvenation and tissue tightening, driven by growing consumer preference for energy-based procedures with minimal downtime. This application leverages the technology's ability to stimulate fibroblast activity and collagen production without the thermal injury associated with aggressive laser therapies. The commercial viability of this segment is underscored by surging consumer interest in non-surgical corrections; According to Apyx Medical, March 2025, in the 'Renuvion wins 2025 NewBeauty Award' press release, consumer searches for "sagging skin" increased by 168.7% in 2024, a demand spike that directly supports the adoption of plasma-based body contouring platforms. As manufacturers align product indications with these cosmetic needs, the market is witnessing a distinct move towards lifestyle-oriented medical devices.

Segmental Insights

The wound healing segment represents the most rapidly expanding area within the global cold plasma in healthcare market, driven by the increasing prevalence of chronic conditions such as diabetic foot ulcers and venous leg ulcers. This growth is primarily attributed to the capacity of cold plasma to eliminate multidrug-resistant pathogens while simultaneously stimulating tissue regeneration. Furthermore, recent clearances by regulatory authorities like the U.S. FDA for plasma-based medical devices have significantly bolstered clinical adoption. These factors collectively position wound management as a critical driver of market expansion, offering effective alternatives to traditional antibiotic therapies.

Regional Insights

North America commands the leading position in the Global Cold Plasma in Healthcare Market, primarily driven by substantial investments in medical research and a robust healthcare infrastructure. The United States contributes significantly to this dominance due to the high adoption rate of plasma-based therapies for chronic wound healing, dermatology, and dentistry. Furthermore, the presence of key industry players and supportive regulatory frameworks, including clearances by the U.S. Food and Drug Administration (FDA) for specific plasma devices, facilitate faster commercialization. These factors collectively establish the region as the central hub for market expansion and technological integration.

Recent Developments

• In October 2025, BioLab Holdings, Inc. entered into a strategic investment and commercialization partnership with Terraplasma Medical GmbH. This collaboration focused on introducing the German company's portable cold atmospheric plasma device to the North American market. The partnership leveraged the manufacturing and distribution strengths of the US-based investor to promote the device, which is designed for the treatment of wounds and skin conditions. The technology, which generates plasma from atmospheric air to inactivate microorganisms and support tissue regeneration, was positioned to offer clinicians a chemical-free solution for infection management and dermatology.
• In July 2025, Adtec Healthcare secured $12 million in funding from new investment partners to drive the global growth of its cold plasma medical solutions. The capital injection was intended to support the development of next-generation devices and facilitate the company’s entry into the United States market. This financial backing was aimed at broadening access to the company's non-invasive technology, which is utilized for wound care and infection control. The funding round represented a strategic milestone, enabling the company to enhance its research and development capabilities while expanding its commercial footprint in key healthcare regions.
• In November 2024, Neoplas Med GmbH deepened its strategic collaboration with Niterra Ventures Company through a significant capital increase. The German medical technology firm secured an additional investment of $18 million from its corporate venture partner to accelerate the global expansion of its argon cold plasma jet technology. This funding was designated to support the scaling of operations and the development of new product platforms, building on the company's success in treating chronic and infected wounds. The investment brought the total backing from the partner to $25 million, reinforcing the shared commitment to establishing cold plasma therapy as a standard of care in international markets.
• In May 2024, US Medical Innovations announced that it had received FDA 510(k) clearance for its new electrosurgical system designed for soft tissue ablation. The regulatory approval covered a cold plasma ablation system that integrates a smart generator with specialized ablators to deliver a plasma jet capable of selectively targeting cells at microscopic surgical margins. This technology utilizes a non-thermal, multi-dimensional plasma-treated electromagnetic field to induce cell death in targeted tissues without damaging surrounding healthy structures. The clearance marked a pivotal step for the company in bringing its proprietary cold plasma technology to the commercial healthcare market for surgical oncology applications.

Key Market Players

• Neoplas med GmbH
• U.S. Medical Innovations LLC
• Terumo Medical Corp
• Adtec Plasma Technology Co Ltd
• Apyx Medical Corp
• Nordson Corp
• Europlasma NV
• Terraplasma GmbH
• Henniker Plasma
• Smith & Nephew plc

By Application	By Region
Wound Healing Surgical Application Other Medical Applications	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cold Plasma in Healthcare Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cold Plasma in Healthcare Market, By Application:

• Wound Healing
• Surgical Application
• Other Medical Applications

• Cold Plasma in Healthcare Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE